News Hub

Panelists from “ Balancing Speed, Safety, and Scale in hPSC-Derived Therapy Development ,” from left: Dr. Richard Carpenedo, Dr. Nika Shakiba, Dr. Ross Jones, Dr. Andrew Gaffney, and Lynn Csontos. Human pluripotent stem cells (hPSCs) offer a renewable ...

Renee Hart, BS LumaCyte United States Picture a familiar scenario: a promising cell therapy program advances through early clinical development on the strength of a phenotypic marker panel and a release assay that was never meant to do more than ...

On behalf of the ISCT Mentoring Group We decided to write this piece for ISCT members to share what we felt was an overwhelmingly positive experience within our mentoring group. Through this article, we aim to describe the values-driven conversations ...

On behalf of the ISCT Mesenchymal Stromal Cell (MSC) Committee Following administration, mesenchymal stromal cells (MSCs) rapidly encounter complex host environments that can shape their fate and function. These environments include blood components, ...

On behalf of the ISCT Australia & New Zealand (ANZ) Regional Early Stage Professionals (ESP) Subcommittee The ISCT ANZ Regional Meeting 2026, held in Melbourne, brought together more than 250 delegates for an intensive 2.5-day program showcasing ...